Abstract
Tankyrase 1 (TNKS1) and tankyrase 2 (TNKS2) enzymes belong to the poly (ADP-ribose) polymerase (PARP) family participates in process of poly-ADP-ribosylation of different target proteins which leads to ubiquitin-mediated proteasomal degradation. Tankyrases are also involved in the pathophysiology of many diseases, especially cancer. Their functions include cell cycle homeostasis (primarily in mitosis), telomere maintenance, Wnt signaling pathway regulation, and insulin signaling (particularly GLUT4 translocation). Studies have implicated that genetic changes, mutations in the tankyrase coding sequence, or up regulation and down regulation of tankyrase are reflected in the numerous disease conditions. Investigations are pursued to develop putative molecules that target tankyrase in various diseases such as cancer, obesity, osteoarthritis, fibrosis, cherubism, and diabetes, thereby providing a new therapeutic treatment option. In the present review, we described the structure and function of tankyrase along with its role in different disease conditions. Furthermore, we also presented cumulative experimental evidences of different drugs acting on tankyrase.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
References
Arqués O, Chicote I, Puig I et al (2016) Tankyrase inhibition blocks Wnt/β-catenin pathway and reverts resistance to PI3K and AKT inhibitors in the treatment of colorectal cancer. Clin Cancer Res an off J Am Assoc Cancer Res 22:644–656. https://doi.org/10.1158/1078-0432.CCR-14-3081
Bao R, Christova T, Song S et al (2012) Inhibition of tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells. PLoS One 7:e48670. https://doi.org/10.1371/journal.pone.0048670
Bartelt A, Heeren J (2014) Adipose tissue browning and metabolic health. Nat Rev Endocrinol 10:24–36. https://doi.org/10.1038/nrendo.2013.204
Bastakoty D, Saraswati S, Cates J et al (2015) Inhibition of Wnt/β-catenin pathway promotes regenerative repair of cutaneous and cartilage injury. FASEB J off Publ Fed Am Soc Exp Biol 29:4881–4892. https://doi.org/10.1096/fj.15-275941
Baumeister W, Walz J, Zühl F, Seemüller E (1998) The proteasome: paradigm of a self-compartmentalizing protease. Cell 92:367–380. https://doi.org/10.1016/s0092-8674(00)80929-0
Bergmann C, Akhmetshina A, Dees C et al (2011) Inhibition of glycogen synthase kinase 3β induces dermal fibrosis by activation of the canonical Wnt pathway. Ann Rheum Dis 70:2191–2198. https://doi.org/10.1136/ard.2010.147140
Bhardwaj A, Yang Y, Ueberheide B, Smith S (2017) Whole proteome analysis of human tankyrase knockout cells reveals targets of tankyrase-mediated degradation. Nat Commun 8:2214. https://doi.org/10.1038/s41467-017-02363-w
Bisht KK, Dudognon C, Chang WG et al (2012) GDP-mannose-4,6-dehydratase is a cytosolic partner of tankyrase 1 that inhibits its poly(ADP-ribose) polymerase activity. Mol Cell Biol 32:3044–3053. https://doi.org/10.1128/MCB.00258-12
Blackburn EH, Gall JG (1978) A tandemly repeated sequence at the termini of the extrachromosomal ribosomal RNA genes in Tetrahymena. J Mol Biol 120:33–53. https://doi.org/10.1016/0022-2836(78)90294-2
Bukhari MH, Qamar S, Batool F (2019) Differential diagnosis of osteogenic tumors in the context of osteosarcoma. In: Cable MG, Randall RL (eds) Osteosarcoma. IntechOpen, Rijeka
Busch AM, Johnson KC, Stan RV et al (2013) Evidence for tankyrases as antineoplastic targets in lung cancer. BMC Cancer 13:211. https://doi.org/10.1186/1471-2407-13-211
Callow MG, Tran H, Phu L et al (2011) Ubiquitin ligase RNF146 regulates tankyrase and Axin to promote Wnt signaling. PLoS One 6:e22595. https://doi.org/10.1371/journal.pone.0022595
Chang W, Dynek JN, Smith S (2005) NuMA is a major acceptor of poly(ADP-ribosyl)ation by tankyrase 1 in mitosis. Biochem J 391:177–184. https://doi.org/10.1042/BJ20050885
Chang P, Coughlin M, Mitchison TJ (2009) Interaction between Poly(ADP-ribose) and NuMA contributes to mitotic spindle pole assembly. Mol Biol Cell 20:4575–4585. https://doi.org/10.1091/mbc.e09-06-0477
Cheng C-F, Ku H-C, Lin H (2018) PGC-1α as a pivotal factor in lipid and metabolic regulation. Int J Mol Sci 19. https://doi.org/10.3390/ijms19113447
Chi N-W, Lodish HF (2000) Tankyrase is a golgi-associated mitogen-activated protein kinase substrate that interacts with IRAP in GLUT4 vesicles*. J Biol Chem 275:38437–38444. https://doi.org/10.1074/jbc.M007635200
Chu-Ping M, Slaughter CA, DeMartino GN (1992) Purification and characterization of a protein inhibitor of the 20S proteasome (macropain). Biochim Biophys Acta 1119:303–311. https://doi.org/10.1016/0167-4838(92)90218-3
Cockman ME, Webb JD, Kramer HB et al (2009) Proteomics-based identification of novel factor inhibiting hypoxia-inducible factor (FIH) substrates indicates widespread asparaginyl hydroxylation of ankyrin repeat domain-containing proteins. Mol Cell Proteomics 8:535–546. https://doi.org/10.1074/mcp.M800340-MCP200
Cook BD, Dynek JN, Chang W et al (2002) Role for the related poly(ADP-Ribose) polymerases tankyrase 1 and 2 at human telomeres. Mol Cell Biol 22:332–342. https://doi.org/10.1128/MCB.22.1.332-342.2002
Damale MG, Pathan SK, Shinde DB et al (2020) Insights of tankyrases: a novel target for drug discovery. Eur J Med Chem 207:112712. https://doi.org/10.1016/j.ejmech.2020.112712
de la Roche M, Ibrahim AEK, Mieszczanek J, Bienz M (2014) LEF1 and B9L shield β-catenin from inactivation by Axin, desensitizing colorectal cancer cells to tankyrase inhibitors. Cancer Res 74:1495–1505. https://doi.org/10.1158/0008-5472.CAN-13-2682
Descamps D, Evnouchidou I, Caillens V et al (2020) The role of insulin regulated aminopeptidase in endocytic trafficking and receptor signaling in immune cells. Front Mol Biosci 7:583556. https://doi.org/10.3389/fmolb.2020.583556
Deshmukh V, Hu H, Barroga C et al (2018) A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee. Osteoarthr Cartil 26:18–27. https://doi.org/10.1016/j.joca.2017.08.015
Distler A, Deloch L, Huang J et al (2013) Inactivation of tankyrases reduces experimental fibrosis by inhibiting canonical Wnt signalling. Ann Rheum Dis 72:1575–1580. https://doi.org/10.1136/annrheumdis-2012-202275
Donigian JR, de Lange T (2007) The role of the poly(ADP-ribose) polymerase tankyrase1 in telomere length control by the TRF1 component of the shelterin complex. J Biol Chem 282:22662–22667. https://doi.org/10.1074/jbc.M702620200
Dregalla RC, Zhou J, Idate RR et al (2010) Regulatory roles of tankyrase 1 at telomeres and in DNA repair: suppression of T-SCE and stabilization of DNA-PKcs. Aging (Albany NY) 2:691–708. https://doi.org/10.18632/aging.100210
Dynek JN, Smith S (2004) Resolution of sister telomere association is required for progression through mitosis. Science 304:97–100. https://doi.org/10.1126/science.1094754
Fujita S, Mukai T, Mito T et al (2018) Pharmacological inhibition of tankyrase induces bone loss in mice by increasing osteoclastogenesis. Bone 106:156–166. https://doi.org/10.1016/j.bone.2017.10.017
Guettler S (2016) AXIN shapes tankyrase architecture. Structure 24:1625–1627. https://doi.org/10.1016/j.str.2016.09.003
Guo H-L, Zhang C, Liu Q et al (2012) The Axin/TNKS complex interacts with KIF3A and is required for insulin-stimulated GLUT4 translocation. Cell Res 22:1246–1257. https://doi.org/10.1038/cr.2012.52
Ha G-H, Kim H-S, Go H et al (2012) Tankyrase-1 function at telomeres and during mitosis is regulated by Polo-like kinase-1-mediated phosphorylation. Cell Death Differ 19:321–332. https://doi.org/10.1038/cdd.2011.101
Haikarainen T, Krauss S, Lehtio L (2014) Tankyrases: structure, function and therapeutic implications in cancer. Curr Pharm Des 20:6472–6488. https://doi.org/10.2174/1381612820666140630101525
Hankey W, Frankel WL, Groden J (2018) Functions of the APC tumor suppressor protein dependent and independent of canonical WNT signaling: implications for therapeutic targeting. Cancer Metastasis Rev 37:159–172. https://doi.org/10.1007/s10555-017-9725-6
Hart M, Concordet JP, Lassot I et al (1999) The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr Biol 9:207–210. https://doi.org/10.1016/s0960-9822(99)80091-8
Hsiao SJ, Smith S (2008) Tankyrase function at telomeres, spindle poles, and beyond. Biochimie 90:83–92. https://doi.org/10.1016/j.biochi.2007.07.012
Huang S-MA, Mishina YM, Liu S et al (2009) Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461:614–620. https://doi.org/10.1038/nature08356
Ikegami D, Akiyama H, Suzuki A et al (2011) Sox9 sustains chondrocyte survival and hypertrophy in part through Pik3ca-Akt pathways. Development 138:1507–1519. https://doi.org/10.1242/dev.057802
Im S-A, Lee S, Lee KW et al (2021) A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP/tankyrase in patients with advanced solid tumors. J Clin Oncol 39:3113. https://doi.org/10.1200/JCO.2021.39.15\_suppl.3113
Kang DH, Lee DJ, Lee S et al (2017) Interaction of tankyrase and peroxiredoxin II is indispensable for the survival of colorectal cancer cells. Nat Commun 8:40. https://doi.org/10.1038/s41467-017-00054-0
Kim MK (2018) Novel insight into the function of tankyrase. Oncol Lett 16:6895–6902. https://doi.org/10.3892/ol.2018.9551
Kim MK, Dudognon C, Smith S (2012) Tankyrase 1 regulates centrosome function by controlling CPAP stability. EMBO Rep 13:724–732. https://doi.org/10.1038/embor.2012.86
Kim S, Han S, Kim Y et al (2019) Tankyrase inhibition preserves osteoarthritic cartilage by coordinating cartilage matrix anabolism via effects on SOX9 PARylation. Nat Commun 10:4898. https://doi.org/10.1038/s41467-019-12910-2
Kittaka M, Yoshimoto T, Hoffman H et al (2020) RANKL-independent osteoclastogenesis in the SH3BP2 cherubism mice. Bone Rep 12:100258. https://doi.org/10.1016/j.bonr.2020.100258
Kiyomitsu T, Boerner S (2021) The nuclear mitotic apparatus (NuMA) protein: a key player for nuclear formation, spindle assembly, and spindle positioning. Front cell Dev Biol 9:653801. https://doi.org/10.3389/fcell.2021.653801
Lau T, Chan E, Callow M et al (2013) A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Cancer Res 73:3132–3144. https://doi.org/10.1158/0008-5472.CAN-12-4562
Lehtiö L, Chi N-W, Krauss S (2013) Tankyrases as drug targets. FEBS J 280:3576–3593. https://doi.org/10.1111/febs.12320
Levaot N, Voytyuk O, Dimitriou I et al (2011) Loss of tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism. Cell 147:1324–1339. https://doi.org/10.1016/j.cell.2011.10.045
Li C-Y, Yu S-F (2006) A novel mutation in the SH3BP2 gene causes cherubism: case report. BMC Med Genet 7:84. https://doi.org/10.1186/1471-2350-7-84
Li M, Tan S-Y, Zhang J, You H-X (2013) Effects of paeonol on intracellular calcium concentration and expression of RUNX3 in LoVo human colon cancer cells. Mol Med Rep 7:1425–1430. https://doi.org/10.3892/mmr.2013.1372
Lietman C, Wu B, Lechner S et al (2018) Inhibition of Wnt/β-catenin signaling ameliorates osteoarthritis in a murine model of experimental osteoarthritis. JCI insight 3. https://doi.org/10.1172/jci.insight.96308
Lima GDMG, Almeida JD, Cabral LAG (2010) Cherubism: clinicoradiographic features and treatment. J Oral Maxillofac Res 1:e2. https://doi.org/10.5037/jomr.2010.1202
Liu L, Wang T, Yuan Z et al (2019) Tankyrase(TNKS) inhibiting autophagy promotes the TGF-ß induced EMT process in vitro and bleomycin(BLM) induced pulmonary fibrosis in rats. Eur Respir J 54:PA5386. https://doi.org/10.1183/13993003.congress-2019.PA5386
Liu J, Xiao Q, Xiao J et al (2022) Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther 7:3. https://doi.org/10.1038/s41392-021-00762-6
Livingstone R, Bryant NJ, Boyle JG et al (2022) Diabetes is accompanied by changes in the levels of proteins involved in endosomal GLUT4 trafficking in obese human skeletal muscle. Endocrinol Diabetes Metab 5:e361. https://doi.org/10.1002/edm2.361
Lo KA, Ng PY, Kabiri Z et al (2016) Wnt inhibition enhances browning of mouse primary white adipocytes. Adipocyte 5:224–231. https://doi.org/10.1080/21623945.2016.1148834
Luo W, Lin S-C (2004) Axin: a master scaffold for multiple signaling pathways. Neurosignals 13:99–113. https://doi.org/10.1159/000076563
Manglani K, Dey CS (2020) Tankyrase inhibition augments neuronal insulin sensitivity and glucose uptake via AMPK-AS160 mediated pathway. Neurochem Int 141:104854. https://doi.org/10.1016/j.neuint.2020.104854
Mashimo M, Kita M, Uno A et al (2022) Tankyrase regulates neurite outgrowth through poly(ADP-ribosyl)ation-dependent activation of β-catenin signaling. Int J Mol Sci 23. https://doi.org/10.3390/ijms23052834
McGonigle S, Chen Z, Wu J et al (2015) E7449: a dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling. Oncotarget 6:41307–41323. https://doi.org/10.18632/oncotarget.5846
Menon M, Elliott R, Bowers L et al (2019) A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors. Sci Rep 9:201. https://doi.org/10.1038/s41598-018-36447-4
Mizutani A, Yashiroda Y, Muramatsu Y et al (2018) RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model. Cancer Sci 109:4003–4014. https://doi.org/10.1111/cas.13805
Moon S, Keam B, Hwang MY et al (2015) A genome-wide association study of copy-number variation identifies putative loci associated with osteoarthritis in Koreans. BMC Musculoskelet Disord 16:76. https://doi.org/10.1186/s12891-015-0531-4
Morris EM, Meers GME, Booth FW et al (2012) PGC-1α overexpression results in increased hepatic fatty acid oxidation with reduced triacylglycerol accumulation and secretion. Am J Physiol Gastrointest Liver Physiol 303:G979–G992. https://doi.org/10.1152/ajpgi.00169.2012
Mukai T, Ishida S, Ishikawa R et al (2014) SH3BP2 cherubism mutation potentiates TNF-α-induced osteoclastogenesis via NFATc1 and TNF-α-mediated inflammatory bone loss. J Bone Miner Res Off J Am Soc Bone Miner Res 29:2618–2635. https://doi.org/10.1002/jbmr.2295
Mukai T, Fujita S, Morita Y (2019) Tankyrase (PARP5) Inhibition induces bone loss through accumulation of its substrate SH3BP2. Cells 8. https://doi.org/10.3390/cells8020195
Mukherjee PM, Wang CJ, Chen I-P et al (2010) Cherubism gene Sh3bp2 is important for optimal bone formation, osteoblast differentiation, and function. Am J Orthod Dentofac Orthop 138:140.e1-140.e11. https://doi.org/10.1016/j.ajodo.2009.05.021. (discussion 140-1)
Nakamura T, Hamada F, Ishidate T et al (1998) Axin, an inhibitor of the Wnt signalling pathway, interacts with beta-catenin, GSK-3beta and APC and reduces the beta-catenin level. Genes Cells 3:395–403. https://doi.org/10.1046/j.1365-2443.1998.00198.x
Nie X, Wei X, Ma H et al (2021) The complex role of Wnt ligands in type 2 diabetes mellitus and related complications. J Cell Mol Med 25:6479–6495. https://doi.org/10.1111/jcmm.16663
Ohba S, He X, Hojo H, McMahon AP (2015) Distinct transcriptional programs underlie Sox9 regulation of the mammalian chondrocyte. Cell Rep 12:229–243. https://doi.org/10.1016/j.celrep.2015.06.013
Onuora S (2017) Wnt inhibitor shows potential as a DMOAD. Nat Rev Rheumatol 13:634. https://doi.org/10.1038/nrrheum.2017.164
Ozaki Y, Matsui H, Asou H et al (2012) Poly-ADP ribosylation of Miki by tankyrase-1 promotes centrosome maturation. Mol Cell 47:694–706. https://doi.org/10.1016/j.molcel.2012.06.033
Plummer R, Dua D, Cresti N et al (2020) First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor. Br J Cancer 123:525–533. https://doi.org/10.1038/s41416-020-0916-5
Riffell JL, Lord CJ, Ashworth A (2012) Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Nat Rev Drug Discov 11:923–936. https://doi.org/10.1038/nrd3868
Rubtsova MP, Vasilkova DP, Malyavko AN et al (2012) Telomere lengthening and other functions of telomerase. Acta Naturae 4:44–61
Sbodio JI, Chi N-W (2002) Identification of a tankyrase-binding motif shared by IRAP, TAB182, and human TRF1 but not mouse TRF1: NuMA contains this RXXPDG motif and is a novel tankyrase partner*. J Biol Chem 277:31887–31892. https://doi.org/10.1074/jbc.M203916200
Sbodio JI, Lodish HF, Chi N-W (2002) Tankyrase-2 oligomerizes with tankyrase-1 and binds to both TRF1 (telomere-repeat-binding factor 1) and IRAP (insulin-responsive aminopeptidase). Biochem J 361:451–459. https://doi.org/10.1042/0264-6021:3610451
Seale P, Conroe HM, Estall J et al (2011) Prdm16 determines the thermogenic program of subcutaneous white adipose tissue in mice. J Clin Invest 121:96–105. https://doi.org/10.1172/JCI44271
Seimiya H, Muramatsu Y, Ohishi T, Tsuruo T (2005) Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics. Cancer Cell 7:25–37. https://doi.org/10.1016/j.ccr.2004.11.021
Smith S, de Lange T (2000) Tankyrase promotes telomere elongation in human cells. Curr Biol 10:1299–1302. https://doi.org/10.1016/s0960-9822(00)00752-1
Smith S, Giriat I, Schmitt A, de Lange T (1998) Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science 282:1484–1487. https://doi.org/10.1126/science.282.5393.1484
Sprouse AA, Steding CE, Herbert B-S (2012) Pharmaceutical regulation of telomerase and its clinical potential. J Cell Mol Med 16:1–7. https://doi.org/10.1111/j.1582-4934.2011.01460.x
Stratford EW, Daffinrud J, Munthe E et al (2014) The tankyrase-specific inhibitor JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines. Cancer Med 3:36–46. https://doi.org/10.1002/cam4.170
Su Z, Deshpande V, James DE, Stöckli J (2018) Tankyrase modulates insulin sensitivity in skeletal muscle cells by regulating the stability of GLUT4 vesicle proteins. J Biol Chem 293:8578–8587. https://doi.org/10.1074/jbc.RA117.001058
Tauriello DVF, Maurice MM (2010) The various roles of ubiquitin in Wnt pathway regulation. Cell Cycle 9:3700–3709. https://doi.org/10.4161/cc.9.18.13204
Thorens B, Mueckler M (2010) Glucose transporters in the 21st century. Am J Physiol Endocrinol Metab 298:E141–E145. https://doi.org/10.1152/ajpendo.00712.2009
Thorsell A-G, Ekblad T, Karlberg T et al (2017) Structural basis for potency and promiscuity in poly(ADP-ribose) polymerase (PARP) and tankyrase inhibitors. J Med Chem 60:1262–1271. https://doi.org/10.1021/acs.jmedchem.6b00990
Tian X-H, Hou W-J, Fang Y et al (2013) XAV939, a tankyrase 1 inhibitior, promotes cell apoptosis in neuroblastoma cell lines by inhibiting Wnt/β-catenin signaling pathway. J Exp Clin Cancer Res 32:100. https://doi.org/10.1186/1756-9966-32-100
Waaler J, Machon O, von Kries JP et al (2011) Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth. Cancer Res 71:197–205. https://doi.org/10.1158/0008-5472.CAN-10-1282
Waaler J, Machon O, Tumova L et al (2012) A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res 72:2822–2832. https://doi.org/10.1158/0008-5472.CAN-11-3336
Wang H, Kuusela S, Rinnankoski-Tuikka R et al (2020) Tankyrase inhibition ameliorates lipid disorder via suppression of PGC-1α PARylation in db/db mice. Int J Obes (lond) 44:1691–1702. https://doi.org/10.1038/s41366-020-0573-z
Wong NACS, Pignatelli M (2002) Beta-catenin–a linchpin in colorectal carcinogenesis? Am J Pathol 160:389–401. https://doi.org/10.1016/s0002-9440(10)64856-0
Wu M, Xu K, Xie Y et al (2019) Diagnostic and management options of osteoblastoma in the spine. Med Sci Monit Int Med J Exp Clin Res 25:1362–1372. https://doi.org/10.12659/MSM.913666
Yan Y, Lackner MR (2012) FOXO3a and β-catenin co-localization: double trouble in colon cancer? Nat Med 18:854–856
Yazici Y, McAlindon TE, Fleischmann R et al (2017) A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study. Osteoarthr Cartil 25:1598–1606. https://doi.org/10.1016/j.joca.2017.07.006
Yeh T-YJ, Sbodio JI, Nguyen MTA et al (2005) Tankyrase-1 overexpression reduces genotoxin-induced cell death by inhibiting PARP1. Mol Cell Biochem 276:183–192. https://doi.org/10.1007/s11010-005-4059-z
Yeh T-YJ, Sbodio JI, Chi N-W (2006) Mitotic phosphorylation of tankyrase, a PARP that promotes spindle assembly, by GSK3. Biochem Biophys Res Commun 350:574–579. https://doi.org/10.1016/j.bbrc.2006.09.080
Yeh T-YJ, Sbodio JI, Tsun Z-Y et al (2007) Insulin-stimulated exocytosis of GLUT4 is enhanced by IRAP and its partner tankyrase. Biochem J 402:279–290. https://doi.org/10.1042/BJ20060793
Zaiss DM, Standera S, Holzhütter H et al (1999) The proteasome inhibitor PI31 competes with PA28 for binding to 20S proteasomes. FEBS Lett 457:333–338. https://doi.org/10.1016/s0014-5793(99)01072-8
Zhang Y, Liu S, Mickanin C et al (2011) RNF146 is a poly(ADP-ribose)-directed E3 ligase that regulates axin degradation and Wnt signalling. Nat Cell Biol 13:623–629. https://doi.org/10.1038/ncb2222
Zhong L, Ding Y, Bandyopadhyay G et al (2016) The PARsylation activity of tankyrase in adipose tissue modulates systemic glucose metabolism in mice. Diabetologia 59:582–591. https://doi.org/10.1007/s00125-015-3815-1
Author information
Authors and Affiliations
Contributions
GS, VS, and CP jointly developed the concept of the article. VS, JB, CP, and SP analyzed and took the lead in the writing process. VS, JB, CP, and DS contributed to the writing and editing of the paper. All authors read and approved the manuscript. The authors confirm that no paper mill and artificial intelligence was used.
Corresponding author
Ethics declarations
Ethical approval
Not applicable.
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Sagathia, V., Patel, C., Beladiya, J. et al. Tankyrase: a promising therapeutic target with pleiotropic action. Naunyn-Schmiedeberg's Arch Pharmacol 396, 3363–3374 (2023). https://doi.org/10.1007/s00210-023-02576-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-023-02576-5